Biogen past years in among best in biotech sector

In the recent years Biogen had a very positive price momentum. Because of the huge return over the past 10 years of 416 percent the share belongs to the top of the biotech companies. Shares of the sector delivered the past 10 years a gain of at around 598 percent.

Returns Biogen versus biotech sector

Returns stock Biogen over several periods, excluding dividend returns

Since 2012 the stock has a loss of 13 percent. over the past 90 days the stock made a loss of 30 percent.

Core figures American biotech sector

The sector trades now at 60 times the earnings per share. The sector trades now at 10,31 times the book value per share. Since 2012 the sector has a profit of 191 percent and since 2007 a profit of 598 percent.

For this year Biogen's revenue will be around 13,91 billion USD. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 13,45 billion USD.

Historical revenues and results Biogen plus estimates 2019

The analysts expect for 2019 a net profit of 5,73 billion USD. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 29,64 USD. The PE-ratio therefore is 7,79.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 0,5 percent.

Newest target prices around 234 USD

Based on the current number of outstanding shares Biogen's market capitalization is 48,85 billion USD. The Biogen stock was the past 12 months quite volatile. Since last May the stock is 16 percent lower. This year the stock price moved between 216 and 389 dollar.

Historical stock prices Biogen

On Monday the stock closed at 230,98 USD.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.